Interventional Oncology Market

Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global Forecast to 2026

Report Code: MD 6975 May, 2021, by marketsandmarkets.com

[215 Pages Report] The global interventional oncology market size is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2020, at a CAGR of 6.8% during the forecast period. The global interventional oncology market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, rising incidence of oncology and increased funding and public-private investments are some of the key factors driving the growth of the interventional oncology market.

Interventional Oncology Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the global interventional oncology market

The COVID-19 pandemic has significantly affected the interventional oncology market. The market is facing challenges in the manufacturing and supply chain, such as delivering products to end users in a timely manner as well as attending to an uneven demand for the products and services in the sector. In addition, a dearth of skilled lab professionals to conduct/study diagnostic tests, limited operations in most of the industries, inadequate funding for research and academic institutes, temporary closure of major academic institutes, disrupted supply chain, and challenges in providing essential/post-sales services due to lockdowns have led to the reduced supply of interventional oncology products to end users. Australia has experienced a significantly lower incidence of COVID-19. Thus, the pandemic is not estimated to have long-term effects on the fundamental growth drivers or end users in the interventional oncology market.

Interventional oncology  Market Dynamics

Driver: Rising patient preference for minimally invasive procedures

In recent years, the demand for minimally invasive procedures has witnessed a significant increase owing to the advantages offered by these procedures over traditional treatment procedures. The key advantages of minimally invasive procedures include fewer operative complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infection, reduced post-operative care, and quicker recovery. Minimally invasive procedures make use of advanced technologies to diagnose and treat various diseases, including cancer. These procedures are used as an effective approach to removing cancer tumors and lymph nodes without scarring. Minimally invasive techniques also assist surgeons in collecting tissues for biopsy as well as in accurate staging studies. This, in turn, helps surgeons in making an appropriate and exact cancer treatment plan. The adoption of minimally invasive techniques also results in significant cost savings. The key players in the interventional oncology market are increasingly focusing on launching novel technologically advanced products. Innovation in this market focuses on developing economical, technologically advanced, and easy-to-use interventional oncology systems. Such advancements focus on improving the functionality of interventional oncology systems and on expanding their application areas, thereby driving the demand for these systems among end users

Restraint: Dearth of well-trained and skilled radiologists and oncologists

The interventional oncology market is witnessing continuous technological innovations and advancements to make the devices and techniques more accurate and specific. However, interventional oncology is a technique wherein high standards can only be achieved and maintained by full-time specialists. As a result, the shortage of well-trained and skilled radiologists and oncologists is expected to affect the growth of the interventional oncology market. For instance, a shortage of more than 2,300 medical oncologists is expected in the US by 2025 (Source: Journal of Global Oncology). The effect of this factor will be more pronounced in developing and underdeveloped regions. One of the major obstacles in delivering care for patients with curable cancers in the sub-Saharan African region is the shortage of medical oncologists, radiation oncologists, and other healthcare workers required for cancer care. Similarly, India is also facing an acute shortage of oncologists, radiotherapists, and surgical oncologists. With 1.8 million cancer patients in the country, only one oncologist treats every 2,000 patients. This shortage of oncologists and radiologists in several countries across the globe is expected to affect the adoption of interventional oncology procedures in their respective healthcare systems despite the presence of a large target patient population.

Opportunity: Emerging economies offer high growth potential

Rapid economic development and increasing healthcare expenditure in several emerging countries such as China, India, Brazil, and Mexico are expected to improve access to quality healthcare in these countries. This is considered a positive indicator for the growth of the interventional oncology market.

The rising incidence of cancer in these countries results in a growth in the demand for various interventional oncology products and procedures. According to GLOBOCAN 2018, there were 609,596 new liver cancer cases in the Asian region in 2018, and this figure is projected to increase by 142,982 by 2025. As a result of the growing disease burden, governments in several emerging countries invest heavily in the development and modernization of their respective healthcare infrastructures. For instance, the healthcare expenditure in China increased in 2016, as fiscal spending on healthcare grew by 10% year-on-year. According to the National Health and Family Planning Commission (NHFPC), the health budget of China for 2016 was USD 0.18 trillion. Likewise, the Indian government has initiated the Ayushman Bharat scheme, through which the government will provide USD 7,030 (INR 5 lakh) per family per year to a population of over 500 million. This scheme will provide a comprehensive screening to individuals over the age of 30 for several diseases, including cancer.

Challenge: Limited clinical data to support therapeutic efficacy

For a treatment to be implemented as a standard of care, there is a requirement of rigorous safety data from Phase I trials, demonstrated efficacy from Phase II trials, and evaluation of clinical outcomes better than available treatments from randomized, controlled Phase III trials. However, in interventional oncology procedures, conducting well-controlled clinical trials is difficult due to the lack of established methodologies. For instance, chemoembolization is the most commonly used procedure for hepatocellular carcinoma. However, the clinical evidence supporting chemoembolization is weak, and the clinical benefits derived through the current trials are lower than the other available treatment options for cancer.

Thus, the limited clinical evidence supporting the benefits of interventional oncology as well as incorporating strategies to improve the therapeutic outcomes and safety of interventional oncology practices are considered key challenges for the growth of this market during the forecast period.

Interventional Oncology Market  by Region

The embolization devices segment to witness the highest share in interventional oncology market, by product, during the forecast period.

In 2020, embolization devices accounted for a share of the interventional oncology market. Embolization devices include non-radioactive embolic agents and radioembolic agents. Although these devices are primarily employed to treat hepatocellular carcinoma, their use has been widely extended to various other forms of cancer. These devices are used when tumors cannot be treated using ablation techniques and in cases where the tumor size is large. They are also used in palliative procedures and as a pre-operative procedure to improve the outcome of liver resection.

Embolic agents include radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents include gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA). Gelatin foam is a non-radioactive embolic agent and is considered a temporary embolic agent whose effect is relatively shorter. Other non-radioactive embolic agents are considered permanent agents whose effects are seen for a longer period.

The liver cancer accounted for the largest share of the interventional oncology market, by application, in 2020.

Liver cancer accounted for the largest share of the interventional oncology market in 2020. Interventional oncology plays a crucial role in treating liver cancer, as removing the tumor with surgery may not leave the tissue healthy enough for effective liver functioning. Thus, primary liver tumors or liver tumors resulting from metastatic cancers can effectively be treated using interventional oncology procedures. Owing to this, more than half of all treatments for primary and metastatic liver cancer are conducted using interventional oncology.

The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities to develop advanced liver cancer therapies using interventional oncology. In addition, initiatives in the form of grants and funding for the development of advanced therapies using interventional oncology also fuel market growth.

The Hospitals & diagnostic centers segment accounted for the largest share of the interventional oncology market, by end users, in 2020

Hospitals & diagnostic centers accounted for the largest share of the interventional oncology market in 2020. The availability of state-of-the-art facilities for treating disorders and injuries and trained personnel has ensured a steady demand for hospital-based care. The inflow of patients is considerably higher in hospitals than in other healthcare settings, which is another key driver for market growth.

Hospitals routinely conduct a wide range of surgical procedures, and most of these surgeries are performed in hospital in-patient settings. Growth in this segment is primarily attributed to the growing number of minimally invasive surgeries and electrosurgery procedures performed in hospitals and the adoption of robotic surgery.

The Asia Pacific market to grow at the highest CAGR during the forecast period.

The interventional oncology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increased funding , supportive regulations for the development and commercialization of advanced interventional oncology products, rising healthcare expenditure, increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of surgeries are the major factors driving the growth of the APAC  interventional oncology market.

Interventional Oncology Market  by Region

Key Market Players

Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea).

Boston Scientific (US) dominated the global interventional oncology market in 2020. The company mainly focuses on growth strategies such as acquisitions and expansions to increase its market presence and product offerings. The company’s plan to acquire BTG will help expand its product offerings in chemoembolization, radioembolization, and ablation therapies. Boston Scientific constantly strives to gain regulatory and reimbursement approvals. As a part of its long-term growth strategy, the company invests in fast-growing markets as well as new markets by strengthening its position in the global healthcare market.

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Units

Value (USD Billion)

Segments Covered

Product, Procedure, Cancer Type, End Users and Region

Geographies Covered

North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, and RoE), APAC (Japan, China, India, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA

Companies Covered

Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea)

This research report categorizes the interventional oncology market based on product, procedure, cancer type, end user, and region.

By Product

  •  Embolization Devices
    • Radioembolic Agents
    • Non-Radio embolic Agents
      • Microspheres
      • Coated Beads
      • Microparticles
  • Ablation Devices
    • Radiofrequency (RF) Ablation Devices
    • Microwave Ablation Devices
    • Cryoablation Devices
    • Other Ablation Devices
  • Support Devices
    • Microcatheters
    • Guidewires

By Procedure

  • Thermal Tumor Ablation
  • Non-Thermal Tumor Ablation
  • Transcatheter Arterial Chemoembolization
  • Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
  • Transcatheter Arterial Embolization/Bland Embolization

By Cancer Type

  • Liver Cancer
  • Lung Cancer
  • Bone Metastasis
  • Kidney Cancer
  • Breast Cancer
  • Prostate Cancer
  • Other Cancers

By End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Recent Developments

  • In 2021, Boston Scientific (US) launched Launched the TheraSphere Y-90 Glass Microspheres
  • In 2018, Merit Medical Systems (US) launched the Preclude IDeal Hydrophilic Sheath Introducer in EMEA markets
  • In 2018, IMBiotechnologies (US) launched ‘Ekobi 500 Embolization Microspheres’ with an enhanced feature of detectability using ultrasound technology.
  • In 2018, Medical City and distributor Gulf Medical Company to install the first IMRIS Surgical Theatre in Saudi Arabia.
  • In 2018, Medtronic (Ireland) launched its OptiSphere embolization spheres designed for hypervascular tumor embolization in the US

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
           FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET: RESEARCH METHODOLOGY STEPS
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL INTERVENTIONAL ONCOLOGY MARKET
                    FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    2.2 MARKET SIZE ESTIMATION
           2.2.1 PRODUCT-BASED MARKET ESTIMATION
                    FIGURE 5 INTERVENTIONAL ONCOLOGY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                    FIGURE 6 INTERVENTIONAL ONCOLOGY MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
           2.2.2 PRIMARY RESEARCH VALIDATION
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 8 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2020 VS. 2026 (USD MILLION)
    FIGURE 9 INTERVENTIONAL ONCOLOGY MARKET SHARE, BY PROCEDURE, 2020
    FIGURE 10 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2020 VS. 2026 (USD MILLION)
    FIGURE 11 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2020 VS. 2026 (USD MILLION)
    FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE INTERVENTIONAL ONCOLOGY MARKET

4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 INTERVENTIONAL ONCOLOGY MARKET OVERVIEW
           FIGURE 13 RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES IS DRIVING THE GROWTH OF THE INTERVENTIONAL ONCOLOGY MARKET
    4.2 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT
           FIGURE 14 EMBOLIZATION DEVICES TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
    4.3 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT (2020)
           FIGURE 15 EMBOLIZATION DEVICES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
    4.4 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE (2020)
           FIGURE 16 LIVER CANCER COMMANDED THE LARGEST SHARE OF THE EUROPEAN INTERVENTIONAL ONCOLOGY MARKET IN 2020
    4.5 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2020 VS. 2026 (USD MILLION)
           FIGURE 17 HOSPITALS TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
    4.6 GEOGRAPHICAL SNAPSHOT OF THE INTERVENTIONAL ONCOLOGY MARKET
           FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR IN THE INTERVENTIONAL ONCOLOGY MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 INTERVENTIONAL ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising patient preference for minimally invasive procedures
                    5.2.1.2 Expansion of the target patient population
                    5.2.1.3 Increasing public-private funding and government support for interventional oncology
                    5.2.1.4 Technological advancements in interventional oncology
           5.2.2 RESTRAINTS
                    5.2.2.1 Dearth of well-trained and skilled radiologists and oncologists
                    5.2.2.2 Unfavorable regulations
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging economies offer high growth potential
                    5.2.3.2 Rising awareness about the benefits of interventional oncology
           5.2.4 CHALLENGES
                    5.2.4.1 Limited clinical data to support therapeutic efficacy
                    5.2.4.2 Strong market positioning of alternative therapies
    5.3 MARKET TRENDS
           5.3.1 PERSONALIZED OR PRECISION INTERVENTIONAL ONCOLOGY
    5.4 REGULATORY SCENARIO
           5.4.1 US
                    5.4.1.1 Japan
                               TABLE 1 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
    5.5 ECOSYSTEM COVERAGE
    5.6 VALUE CHAIN ANALYSIS
    5.7 PRICING ANALYSIS

6 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT (Page No. - 64)
    6.1 INTRODUCTION
           TABLE 2 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 EMBOLIZATION DEVICES
           TABLE 3 RECENT PRODUCT LAUNCHES AND APPROVALS OF EMBOLIZATION DEVICES
           TABLE 4 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 5 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.2.1 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT, BY PROCEDURE
                    TABLE 6 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
           6.2.2 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT, BY CANCER TYPE
                    TABLE 7 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.2.3 RADIOEMBOLIC AGENTS
                    6.2.3.1 Radioembolic agents dominated the interventional oncology embolization devices market
                               TABLE 8 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
                               TABLE 9 RADIOEMBOLIC AGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
                               6.2.3.1.1 Radioembolic agents market split, by procedure
                                            TABLE 10 RADIOEMBOLIC AGENTS MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                               6.2.3.1.2 Radioembolic agents market split, by cancer type
                                            TABLE 11 RADIOEMBOLIC AGENTS MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.2.4 NON-RADIOACTIVE EMBOLIC AGENTS
                    6.2.4.1 Embolization procedures cannot be used to treat cancers in advanced stages, which is a major factor restraining market growth
                               TABLE 12 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
                               TABLE 13 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 14 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
                               6.2.4.1.1 Non-radioactive embolic agents market split, by procedure
                                            TABLE 15 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                               6.2.4.1.2 Non-radioactive embolic agents market split, by cancer type
                                            TABLE 16 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
                    6.2.4.2 Microspheres
                               6.2.4.2.1 Preference for alternative procedures limits the growth of this market segment
                                            TABLE 17 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2019–2026 (USD MILLION)
                    6.2.4.3 Coated beads
                               6.2.4.3.1 Coated beads are better at finding CTC cancer, driving the growth of this market segment
                                            TABLE 18 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2019–2026 (USD MILLION)
                    6.2.4.4 Microparticles
                               6.2.4.4.1 Microparticles can be used in various cancer applications—a key factor driving growth
                                            TABLE 19 MAJOR BRANDS OF MICROCARRIERS
                                            TABLE 20 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2019–2026 (USD MILLION)
    6.3 ABLATION DEVICES
           TABLE 21 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 22 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.3.1 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET SPLIT, BY PROCEDURE
                    TABLE 23 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
           6.3.2 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET SPLIT, BY CANCER TYPE
                    TABLE 24 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.3.3 RADIOFREQUENCY (RF) ABLATION DEVICES
                    6.3.3.1 Growing competition among different technologies offered by key players, backed by long-term clinical efficacy data, to drive the RF ablation devices market 80
                               TABLE 25 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS
                               TABLE 26 RADIOFREQUENCY ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               6.3.3.1.1 Radiofrequency ablation devices market split, by procedure
                                            TABLE 27 RADIOFREQUENCY ABLATION DEVICES MARKET, BY PROCEDURE,2019–2026 (USD MILLION)
                               6.3.3.1.2 Radiofrequency ablation devices market split, by cancer type
                                            TABLE 28 RADIOFREQUENCY ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.3.4 MICROWAVE ABLATION DEVICES
                    6.3.4.1 Microwave ablation enables the simultaneous treatment of multiple lesions—a key factor driving market growth
                               TABLE 29 MICROWAVE ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               6.3.4.1.1 Microwave ablation devices market split, by procedure
                                            TABLE 30 MICROWAVE ABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                               6.3.4.1.2 Microwave ablation devices market split, by cancer type
                                            TABLE 31 MICROWAVE ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.3.5 CRYOABLATION DEVICES
                    6.3.5.1 Advantages of cryoablation over other thermal ablation techniques to drive market growth in the coming years
                               TABLE 32 CRYOABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               6.3.5.1.1 Cryoablation devices market split, by procedure
                                            TABLE 33 CRYOABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                               6.3.5.1.2 Cryoablation devices market split, by cancer type
                                            TABLE 34 CRYOABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.3.6 OTHER ABLATION DEVICES
                    TABLE 35 OTHER ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    6.3.6.1 Other ablation devices market split, by procedure
                               TABLE 36 OTHER ABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                    6.3.6.2 Other ablation devices market split, by cancer type
                               TABLE 37 OTHER ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
    6.4 SUPPORT DEVICES
           TABLE 38 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 39 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.4.1 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT, BY PROCEDURE
                    TABLE 40 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
           6.4.2 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT, BY CANCER TYPE
                    TABLE 41 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           6.4.3 MICROCATHETERS
                    6.4.3.1 Regulatory approvals driving the growth of the microcatheters market
                               TABLE 42 MICROCATHETERS MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.4.4 GUIDEWIRES
                    6.4.4.1 Advancements in guidewire construction and the launch of new and advanced products are the major factors driving the growth of this market
                               TABLE 43 GUIDEWIRES MARKET, BY REGION, 2019–2026 (USD MILLION)

7 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE (Page No. - 91)
    7.1 INTRODUCTION
           TABLE 44 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
           7.1.1 LIVER CANCER
                    7.1.1.1 Increasing disease prevalence and rising research activities are driving market growth
                               TABLE 45 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.1.2 KIDNEY CANCER
                    7.1.2.1 For patients with small lesions, cryoablation is considered a first-line therapy as it preserves more kidney tissue than surgery
                               TABLE 46 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.1.3 BREAST CANCER
                    7.1.3.1 Growing number of breast cancer cases across the globe is fueling the adoption of IORT
                               TABLE 47 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.1.4 LUNG CANCER
                    7.1.4.1 Increasing number of cancer cases will drive the demand for interventional oncology procedures
                               TABLE 48 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.1.5 BONE CANCER
                    7.1.5.1 Interventional oncology procedures can eliminate tumors directly and relieve pain
                               TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.1.6 PROSTATE CANCER
                    7.1.6.1 Technological advancements in radiology devices to fuel the adoption of interventional oncology for prostate cancer treatment
                               TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.1.7 OTHER CANCERS
                    TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)

8 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE (Page No. - 99)
    8.1 INTRODUCTION
           TABLE 52 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
    8.2 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT)
           8.2.1 TARE SHOWS GREATER CLINICAL EFFICACY THAN TACE—A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 53 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
           8.3.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS—A MAJOR FACTOR DRIVING THE DEMAND FOR TACE PROCEDURES
                    TABLE 54 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.4 THERMAL TUMOR ABLATION
           8.4.1 GROWING CLINICAL EVIDENCE PROVING THE EFFICACY OF THERMAL TUMOR ABLATION IN THE TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH
                    TABLE 55 THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.5 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE)
           8.5.1 INCREASING CLINICAL EVIDENCE FOR TARE AND TACE TO RESTRAIN THE GROWTH OF THIS MARKET
                    TABLE 56 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.6 NON-THERMAL TUMOR ABLATION
           8.6.1 NANOKNIFE HAS EMERGED AS A POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TECHNIQUES
                    TABLE 57 NON-THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)

9 INTERVENTIONAL ONCOLOGY MARKET, BY END USER (Page No. - 107)
    9.1 INTRODUCTION
           TABLE 58 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.2 HOSPITALS
           9.2.1 HIGH PURCHASING POWER AND INCREASING NUMBER OF SURGERIES IN HOSPITALS TO SUPPORT THE GROWTH OF THIS SEGMENT
                    TABLE 59 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
    9.3 AMBULATORY SURGERY CENTERS
           9.3.1 INCREASING NUMBER OF AMBULATORY SURGERY CENTERS TO DRIVE MARKET GROWTH
                    TABLE 60 INTERVENTIONAL ONCOLOGY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2019–2026 (USD MILLION)
    9.4 RESEARCH & ACADEMIC INSTITUTES
           9.4.1 BUDGETARY RESTRICTIONS IN RESEARCH & ACADEMIC INSTITUTES ARE LIMITING THE ADOPTION OF HIGH-END INTERVENTIONAL ONCOLOGY PRODUCTS
                    TABLE 61 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)

10 INTERVENTIONAL ONCOLOGY MARKET, BY REGION (Page No. - 112)
     10.1 INTRODUCTION
           TABLE 62 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 20 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
             TABLE 63 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 64 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 65 NORTH AMERICA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 66 NORTH AMERICA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 67 NORTH AMERICA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 68 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 69 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 US to dominate the North American interventional oncology market
                                     TABLE 70 US: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 71 US: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 72 US: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 73 US: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Public-private initiatives to support the adoption of interventional oncology procedures in Canada
                                     TABLE 74 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,2019–2026 (USD MILLION)
                                     TABLE 75 CANADA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 76 CANADA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 77 CANADA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
     10.3 EUROPE
             TABLE 78 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 79 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,2019–2026 (USD MILLION)
             TABLE 80 EUROPE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 81 EUROPE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 82 EUROPE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 83 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 84 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany is the fastest-growing market in Europe
                                     TABLE 85 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 86 GERMANY: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 87 GERMANY: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 88 GERMANY: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Increasing awareness and support for cancer-related activities to drive market growth in the UK
                                     TABLE 89 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 90 UK: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 91 UK: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 92 UK: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Radiofrequency ablation dominated the ablation devices market in France
                                     TABLE 93 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 94 FRANCE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 95 FRANCE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 96 FRANCE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Growing awareness about cancer and treatment options to support market growth in Italy
                                     TABLE 97 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 98 ITALY: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 99 ITALY: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 100 ITALY: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Growing geriatric population is a major factor driving market growth
                                     TABLE 101 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 102 SPAIN: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 103 SPAIN: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 104 SPAIN: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
                         TABLE 105 ROE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,2019–2026 (USD MILLION)
                         TABLE 106 ROE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 107 ROE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 108 ROE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 21 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
             TABLE 109 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 110 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 111 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 112 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 113 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 114 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 115 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Rising geriatric population and universal healthcare reimbursement are the major driving factors
                                     TABLE 116 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 117 JAPAN: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 118 JAPAN: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 119 JAPAN: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing cancer incidence and growing patient population to drive market growth in China
                                     TABLE 120 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 121 CHINA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 122 CHINA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 123 CHINA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Improving research capabilities coupled with the expansion of key players to drive market growth in India
                                     TABLE 124 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 125 INDIA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 126 INDIA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 127 INDIA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.4.4 AUSTRALIA
                        10.4.4.1 Rising research investments and awareness campaigns are the key factors supporting market growth
                                     TABLE 128 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 129 AUSTRALIA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 130 AUSTRALIA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 131 AUSTRALIA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,BY TYPE, 2019–2026 (USD MILLION)
             10.4.5 SOUTH KOREA
                        10.4.5.1 Rising R&D and promising clinical trials in the country to positively impact market growth
                                     TABLE 132 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 133 SOUTH KOREA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 134 SOUTH KOREA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 135 SOUTH KOREA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
                        TABLE 136 ROAPAC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 137 ROAPAC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 138 ROAPAC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 139 ROAPAC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             TABLE 140 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 141 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 142 LATAM: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 143 LATAM: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 144 LATAM: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 145 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 146 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Brazil to account for the largest share of the Latin American interventional oncology market
                                     TABLE 147 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 148 BRAZIL: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 149 BRAZIL: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 150 BRAZIL: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Growing awareness campaigns and rising incidence of cancer to drive market growth in Mexico
                                     TABLE 151 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 152 MEXICO: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 153 MEXICO: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 154 MEXICO: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                         TABLE 155 ROLA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                         TABLE 156 ROLA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 157 ROLA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 158 ROLA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND RISING INCIDENCE OF CANCER ARE DRIVING GROWTH IN THE MIDDLE EAST & AFRICA
                         TABLE 159 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                         TABLE 160 MEA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 161 MEA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 162 MEA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                         TABLE 163 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 158)
     11.1 OVERVIEW
             FIGURE 22 KEY DEVELOPMENTS IN THE INTERVENTIONAL ONCOLOGY MARKET FROM 2017 TO 2019
     11.2 GLOBAL MARKET SHARE ANALYSIS, 2020
           TABLE 164 MEDICAL TAPES AND BANDAGES MARKET: DEGREE OF COMPETITION
             FIGURE 23 BOSTON SCIENTIFIC HELD THE LEADING POSITION IN THE INTERVENTIONAL ONCOLOGY MARKET IN 2020
     11.3 COMPETITIVE LEADERSHIP MAPPING
     11.4 VENDOR INCLUSION CRITERIA
     11.5 VENDOR DIVE
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
             FIGURE 24 INTERVENTIONAL ONCOLOGY MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2020
     11.6 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2020)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
             FIGURE 25 INTERVENTIONAL ONCOLOGY MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2020 (SME/START-UPS)
     11.7 COMPANY PRODUCT FOOTPRINT ANALYSIS
             TABLE 165 PRODUCT FOOTPRINT OF COMPANIES
             TABLE 166 INDUSTRY FOOTPRINT OF COMPANIES
             TABLE 167 APPLICATION FOOTPRINT OF COMPANIES
             TABLE 168 REGIONAL FOOTPRINT OF COMPANIES
     11.8 COMPETITIVE SCENARIO (2017–2020)
             11.8.1 KEY PRODUCT LAUNCHES
             11.8.2 DEALS

12 COMPANY PROFILES (Page No. - 171)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)* 
             12.1.1 BOSTON SCIENTIFIC CORPORATION
                         TABLE 169 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
                         FIGURE 26 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)
             12.1.2 MEDTRONIC PLC
                         TABLE 170 MEDTRONIC PLC: BUSINESS OVERVIEW
                         FIGURE 27 MEDTRONIC PLC: COMPANY SNAPSHOT (2019)
             12.1.3 JOHNSON & JOHNSON
                         TABLE 171 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                         FIGURE 28 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
             12.1.4 TERUMO CORPORATION
                         TABLE 172 TERUMO CORPORATION: BUSINESS OVERVIEW
                         FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.5 MERIT MEDICAL SYSTEMS, INC.
                         TABLE 173 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
                         FIGURE 30 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2019)
             12.1.6 TELEFLEX, INC.
                         TABLE 174 TELEFLEX, INC.: BUSINESS OVERVIEW
                         FIGURE 31 TELEFLEX, INC.: COMPANY SNAPSHOT (2020)
             12.1.7 ANGIODYNAMICS, INC.
                         TABLE 175 ANGIODYNAMICS, INC.: BUSINESS OVERVIEW
                         FIGURE 32 ANGIODYNAMICS: COMPANY SNAPSHOT (2020)
             12.1.8 BECTON, DICKINSON AND COMPANY
                         TABLE 176 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                         FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             12.1.9 HEALTHTRONICS, INC.
                         TABLE 177 HEALTHTRONICS, INC.: BUSINESS OVERVIEW
             12.1.10 TROD MEDICAL
                         TABLE 178 TROD MEDICAL: BUSINESS OVERVIEW
             12.1.11 SANARUS TECHNOLOGIES, INC.
                         TABLE 179 SANARUS TECHNOLOGIES, INC.: BUSINESS OVERVIEW
             12.1.12 IMBIOTECHNOLOGIES LTD.
                         TABLE 180 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW
             12.1.13 MEDWAVES, INC.
                         TABLE 181 MEDWAVES, INC.: BUSINESS OVERVIEW
             12.1.14 ICECURE MEDICAL
                         TABLE 182 ICECURE MEDICAL: BUSINESS OVERVIEW
             12.1.15 COOK MEDICAL
                         TABLE 183 COOK MEDICAL: BUSINESS OVERVIEW
     12.2 OTHER COMPANIES
             12.2.1 PROFOUND MEDICAL CORP.
             12.2.2 SIRTEX MEDICAL
             12.2.3 BAYLIS MEDICAL COMPANY, INC.
             12.2.4 ACCURAY
             12.2.5 ALPINION MEDICAL SYSTEMS
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 205)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

The study involved four major activities to estimate the current size of the interventional oncology market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the interventional oncology market study.

Primary Research

The interventional oncology market comprises several stakeholders such as Interventional oncology product manufacturing companies, Product distributors and channel partners, Hospitals and surgical centers, Minimally invasive medical devices, ablation, and embolization product manufacturing companies, Commercial service providers, Clinical research organizations (CROs), Ablation and embolization service providers, Medical research laboratories, Academic medical centers and universities, Cancer research organizations, Government and non-governmental regulatory authorities, Market research and consulting firms. The demand side of this market is characterized by the increasing incidence of technological advancements and increased funding and public-private investments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:

Interventional Oncology Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the interventional oncology market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Interventional Oncology Market Size, and Share

Data Triangulation

After arriving at the overall market size-using the market size estimation processes as explained above-the interventional oncology market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the interventional oncology industry.

Report Objectives

  • To define, describe, and forecast the interventional oncology market by product, procedure, cancer type, end user, and region
  • To provide detailed information about the major factors influencing the market growth (such as key drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contributions to the overall interventional oncology market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the revenue of market segments with respect to five major regions, namely,
    North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players active in the interventional oncology market and comprehensively analyze their global revenue shares and core competencies2
  • To track and analyze competitive market-specific developments such as product launches, collaborations, agreements, partnerships, expansions, and mergers & acquisitions in the interventional oncology market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the interventional oncology market report:

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players

Product Analysis

  • Further breakdown of the Rest of European market into Poland, Nederland and other European countries (aggregated)

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 OEMs)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Interventional Oncology Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Interventional Oncology Market

Request For Special Pricing
Report Code
MD 6975
Published ON
May, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Interventional Oncology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved